l
The data of all published IQWiG recommendations and the related G-BA decisions have been exzerpted systematically based on a standard template into the Prismaccess database.
l Prismaccess is a web-based database, which contains information derived from HTA dossiers of national health authorities worldwide including Germany. In a systematic analysis differences between IQWiG recommendations and G-BA decisions on the categories "added benefit" and "probaibility of an added benefit" were assessed quantitatively. l All identified documents where differences have been observed, were then qualitatively compared.
RESULTS:
l We identified multiple levels of differences within the added benefit assessments:
o Differences in decisions on the added benefit -that is that in many cases G-BA changes the perceived added benefit as recommended by IQWiG in a positive decision ("not proven" to "proven") and assigns different (often better) added benefit in the magnitude ("no" to "non-quantifiable"; "minor" to "considerable") even if sometimes only in sub-groups.
o Differences in probabilities of added benefits -that is that G-BA in even more cases changes the probability of an added benefit to more positive ("Hint" to "Indication" or "proven").
o Differences about subgroups -The G-BA evaluates the subgroups preset either within the ACT decisions or by IQWiG during the assessment usually based on a clinical scientific rational. However, we observed that G-BA regroups and summarizes the subgroups again during their appraisal. This can change the result in both directions -positive and negative. Other judgement of the data by the G-BA. [7] Janumet/ Velmetia Indication of an additional benefit; extent not quantifiable. The added benefit is located between minor and major.
Concretization of the result "The added benefit is located between minor and major." through G-BA [20] Xalkori o This analysis did not take into account the possible impact of the evaluation differences into the price negotiations.
o This analysis has not systematically assessed the oral hearings which could have had an important impact on the changes within a G-BA decision.
o This analysis did not differentiate between products where companies submitted new evidence in an addendum (e.g. crizotinib) or where the process was followed straight away.
• The underlying analysis indicates that an research and advice on unmet medical need, disease specific population and potential sub-populations as well as adequate comparator therapies potentially can improve success in submissions.
The poster is available on www.marketaccess-pricingstrategy.de analyzed process
